Approved or Filed
| Indication | Product | Partner | Status |
|---|---|---|---|
| Neutropenia | Neulasta® (pegfilgrastim) |
Amgen | FDA Approved |
| Hepatitis C | PEGASYS® (peginterferon alfa-2a) |
Roche | FDA Approved |
| Hepatitis C | PEG-INTRON® (peginterferon alfa-2b) |
Schering-Plough | FDA Approved |
| Macular Degeneration | Macugen® (pegaptanib sodium) |
(OSI)-Eyetech | FDA Approved Filed in EU |
| Renal Anemia | Mircera™ (continuous erythropoiesis receptor activator) |
Roche | Approved in EU Filed in U.S. |
| Crohn's Disease | Cimzia (peg-anti-TNF alpha antibody fragment) |
UCB Pharma | Approved in U.S. Approved/Launched In Switzerland |
| Rheumatoid Arthritis | Cimzia (peg-anti-TNF alpha antibody fragment) |
UCB Pharma | Filed in U.S. |
| Acromegaly | Somavert® (pegvisomant) |
Pfizer | FDA Approved |
| Cardiac Imaging | DEFINITY® Vial (perflutren lipid microsphere injectable suspension) |
Bristol-Myers Squibb | FDA Approved |
| Cranial Dural Sealant | DuraSeal® Dural Sealant... |
Confluent Surgical | FDA Approved |
Phase 3
| Indication | Product | Partner | Status |
|---|---|---|---|
| Cystic fibrosis-associated lung infection | Tobramycin (TIP™) Tobramycin Inhaled Powder |
Novartis | Phase 3 |
| Prevention of Post-surgical adhesions | SprayGel™ Adhesion Barrier System |
Confluent Surgical | Phase 3 in the U.S. Marketed in Europe |
| Anemia | Hematide™ (synthetic peptide-based, erythropoiesis-stimulating agent) |
Affymax | Phase 3 |
Phase 2
| Indication | Product | Partner | Status |
|---|---|---|---|
| Refractory tumors | NKTR-102 (PEG-irinotecan) |
Proprietary product | Phase 2 |
| Opioid bowel dysfunction, including opioid-induced constipation | NKTR-118 (oral PEG-naloxol) |
Proprietary product | Phase 2 |
| Pneumonia | NKTR-061 (amikacin inhale) |
Bayer | Phase 2 |
| Cystic fibrosis-associated lung infection | Ciprofloxacin (CIP) |
Bayer | Phase 2 |
| Cancer | CDP 791 (peg-antibody fragment angiogenesis inhibitor) |
UCB Pharma | Phase 2 |
| Migraine | MAP0004 (inhaled DHE) |
MAP Pharmaceuticals | Phase 2 |
Phase 1
| Indication | Product | Partner | Status |
|---|---|---|---|
| Aspergillosis | NKTR-024 (amphotericin B inhalation powder) |
Proprietary product | Phase 1 |
| Chemotherapy-induced Anemia in Prostate, Breast and Non-small Cell Lung Cancer | Hematide™ (synthetic peptide-based, erythropoiesis-stimulating agent) |
Affymax | Phase 1 |